Some really interesting findings in the latest Pharmaceutical Strategies Group - PSG Trends in Drug Benefit Design Report. It shows that employers and health plans have a similar approach to GLP-1 coverage for T2D (both above 90%) but varied with their #GLP1 coverage for #obesity — 37% of employers covering it vs. only 23% coverage from health plans. What do you think? Did you expect a higher percentage of coverage?
Vida Health’s Post
More Relevant Posts
-
Download our latest report, "Money Money Money from A Poor Man's Purse," under the Discovery Series and explore why the pharmaceutical industry needs a reset. Download the full report (for free), here https://lnkd.in/d4ShfHqr #publichealth #pharmaceuticals #healthcare #health #publicpolicy #digitalhealth #reset #medicines #money #change #discovery
-
-
#NEW: IQVIA's 2024 report 'Long-term Market Sustainability for Infused Biosimilars in the U.S.' calls on key decisionmakers to initiate urgent action to deliver #biosimilars to all those who need them. "Misaligned incentives around commercial payer rebates can inadvertently promote use of costlier drugs...higher priced originators have been noted as a potential contributor to the limited early coverage of the biosimilar and therefore, slow uptake." Read more here: https://lnkd.in/eUYXaWmS
-
In this episode of the twilight zone healthcare economics learn about -- Biosimilars Specialty drug competition lowering drug prices How middlemen loose revenue Biosimilar related questions to ask your PBM Employer health plans will decide how biosimilars will dominate the future of drug therapy or quietly disappear from the market. #healthcare #pharmacy #healthcareinnovation #patientexperience #medical
The Biosimilar Market and the Influence of PBMs | MakoRx
https://www.makorx.com
-
Transforming Healthcare: The Impact of New Legislation on Insulin Costs In the video transcription, the speaker discusses a law they proposed and signed that none of the Republicans voted for. The law has successfully reduced the cost of insulin for individuals with diabetes from $400 a month to $35 a month, despite it only costing $10 to make. This has allowed for a healthier profit margin for pharmaceutical companies while making the life-saving medication more affordable for those in need. The speaker highlights the impact of this legislation in beating Big Pharma and providing relief to those struggling with the high cost of insulin. #BigPharma #InsulinCosts #HealthcareReform #BidenLaw #RepublicanVote #Diabetes #AffordableMedicine #HealthcareForAll #BreakingNews #vizard
-
Enhance Your Market Strategy: Early Health Economic Evaluations utilize early clinical evidence to identify the patient groups that most benefit from your drug. This strategy assists in shaping your market entry and pricing framework. Customize your product to meet specific requirements by understanding the differences in disease severity and patient responses to your treatments. Learn how our expertise can aid in refining your product for a diverse range of patient profiles. #HEOR #reimbursement #costeffectiveness #pharmaceuticals #HTA #marketaccess
-
-
Please check out the Wall Street Journal today. Great article about sterile compounding and Nephron Pharmaceuticals is, and will be, committed to solving drug shortage needs. Thanks The Wall Street Journal for highlighting this important issue. https://lnkd.in/gRhxxiqD
Drug Shortages Are a Boon to One Industry: Compounding Pharmacies
wsj.com
-
Business Development | Project Management | AI & Advancing Healthcare | Market Access
🌍 Exciting News in the #PharmaIndustry 🏥 The National Institute for Health and Care Excellence (#NICE), the #UK health technology assessor, has given its seal of approval to #Jardiance (#empagliflozin) for a groundbreaking new indication! 🩺 In a significant move, NICE is now recommending Boehringer Ingelheim's Jardiance for the treatment of symptomatic chronic #heartfailure with preserved or mildly reduced ejection fraction in adults. 💡 This recommendation marks a crucial development in the treatment of this condition and offers new hope to patients. Connect, Repost & Follow for more info on the pharmaceutical industry. Let's shape a healthier world together! 🌐 #pharmaceutical #healthcare #Jardiance #chronicheartfailure #NICE #BoehringerIngelheim
-
-
Biden’s 2025 budget includes several legislative proposals supporting the FDA's efforts to protect American consumers and patients. A main suggestion from the budget is to eliminate the statutory distinction between the approval standard for biosimilar and interchangeable biosimilar products. This distinction between biosimilars and interchangeable biosimilars has led to confusion and misunderstanding among patients and health care providers about the safety and effectiveness of biosimilars. The new suggested policy may have significant implications for the US biosimilars markets for patients and providers alike. Read more here: https://lnkd.in/eGGVCEZ3 #biosimilars #USA #Biden #pharma #news
-
📢 The 🆕issue of Australian Prescriber reviews prescribing in three key areas: community-acquired #pneumonia, #hypertension and #Alzheimer disease. Discover the new articles and updates: https://bit.ly/3RFjURG #healthcare #QUM https://lnkd.in/eRYfp9kX
Uncover the nuances of deprescribing antihypertensive drugs for frail older adults. Balancing potential benefits and harms is key for optimal care. Learn more: https://bit.ly/3XuxXwZ Monash University Monash Pharmacy and Pharmaceutical Sciences University of Sydney University of South Australia Reeve Irvine Research Center (UCI) #AustralianPrescriber #healthcare #Deprescribing #AntihypertensiveDrugs
-
Institute for Integrated Healthcare (IIH), & Employer Provider Council (EPC); Rotarian; Innovator & Strategist
1moNot likely, Carole Mendoza , due to a program vacuum that most employers find themselves trapped in by vendor contracts. #epcouncil.org